Cellivery Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
Cellivery Therapeutics Stock Forecast and Price Target
According to experts, who recently provided their 2024 price targets for Cellivery Therapeutics, the average price target is ₩0.00, with a high estimate of ₩0.00 and a low estimate of ₩0.00. That is a potential downside of approximately 0 from the last closing price of ₩6680.00 on March, 2023. Even if you are not interested in A268600 stock, it is still imperative to be aware of its competitors.
N/A
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A278650 Stock Forecast | HLB bioStep | - |
0
|
₩3.53k | Buy/Sell | ₩0.00 | -100.00% |
| A084650 Stock Forecast | LabGenomics | Buy |
2
|
₩2.76k | Buy/Sell | ₩6.00k | 81.49% |
| A038290 Stock Forecast | Macrogen | Buy |
11
|
₩20.30k | Buy/Sell | ₩30.00k | 47.78% |
| A215380 Stock Forecast | WOOJUNG BIO | - |
0
|
₩1.92k | Buy/Sell | ₩0.00 | -100.00% |
| A223250 Stock Forecast | DreamCIS | - |
0
|
₩2.85k | Buy/Sell | ₩0.00 | -100.00% |
Cellivery Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for Cellivery Therapeutics has grown by 2940.87%, going from ₩761.57M to ₩23.16B. In the following year, the 0 analysts surveyed believe that Cellivery Therapeutics's Revenue will decrease by 82.30%, reaching ₩4.10B. Over the next eight years, experts anticipate that Revenue growth for Cellivery Therapeutics will be 22.91%.
.jpg)
Cellivery Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Cellivery Therapeutics's EBITDA has grown, increasing from ₩-16.57B to ₩-62.82B – an increase of 279.06%. For the next year, 0 analysts project Cellivery Therapeutics's EBITDA to drop by 51.01%, reaching ₩-30.78B. By 2030, professionals believe that Cellivery Therapeutics's EBITDA will decrease by 34.91%, reaching ₩-40.89B – a concerning trend for the company.
Cellivery Therapeutics EBIT Forecast for 2023 - 2025 - 2030
Cellivery Therapeutics's EBIT has increased by 286.21% In the last two years, going from ₩-17.61B to ₩-68.02B. According to 0 prominent analysts, Cellivery Therapeutics's EBIT will fall by 51.58% in the next year, reaching ₩-32.94B. By 2030, professionals believe that Cellivery Therapeutics's EBIT will decrease by 35.03%, reaching ₩-44.19B – a concerning trend for the company.
Site Navigation
.jpg)